Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
105Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $40.52M | $-160.06M | $-1.80 |
| 2024 | $32.31M | $-237.09M | $-2.88 |
| 2023 | $78.12M | $-153.22M | $-2.02 |
| 2022 | $19.71M | $-220.43M | $-3.21 |
| 2021 | $25.54M | $-192.50M | $-2.85 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $-0.22 per share
Typical surprise +15.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.15 vs $-0.27beat
- Tue, May 5$-0.26 vs $-0.30beat
- Mon, Mar 9$-0.06 vs $-0.27beat
- Mon, Nov 10$-0.28 vs $-0.38beat
- Tue, Aug 12$-0.63 vs $-0.41miss
- Mon, May 12$-0.43 vs $-0.51beat
Estimates and results for EDIT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
EDIThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newszacks.com·5d ago·Neutral
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
View source ↗